These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27838135)

  • 1. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
    McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
    Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
    Boupaijit K; Suprasert P
    Asian Pac J Cancer Prev; 2016; 17(3):1123-7. PubMed ID: 27039736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
    Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
    Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
    Tinker AV; Fiorino L; O'Dwyer H; Kumar A
    Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
    Machida H; Moeini A; Ciccone MA; Mostofizadeh S; Takiuchi T; Brunette LL; Roman LD; Matsuo K
    Am J Clin Oncol; 2018 Sep; 41(9):851-860. PubMed ID: 28763329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
    Tanigawa T; Matoda M; Yamamoto A; Nomura H; Okamoto S; Sakamoto K; Kondo E; Omatsu K; Kato K; Takeshima N
    Arch Gynecol Obstet; 2016 Mar; 293(3):633-8. PubMed ID: 26305033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
    Pectasides D; Fountzilas G; Papaxoinis G; Pectasides E; Xiros N; Sykiotis C; Koumarianou A; Psyrri A; Panayiotides J; Economopoulos T
    Int J Gynecol Cancer; 2009 May; 19(4):777-81. PubMed ID: 19509587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.
    Coronel J; Cetina L; Candelaria M; González-Fierro A; Arias D; Cantu D; Dueñas-González A
    Med Oncol; 2009; 26(2):210-4. PubMed ID: 19016011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity.
    Manders DB; Kehoe SM; Miller DS; Lea JS; Richardson DL
    Am J Clin Oncol; 2018 Aug; 41(8):797-801. PubMed ID: 28225444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
    Song M; DiPaola RS; Cracchiolo BM; Gibbon DG; Hellmann M; Nieves-Neira W; Vaidya A; Wagreich AR; Shih WJ; Rodriguez-Rodriguez L
    Int J Gynecol Cancer; 2014 Nov; 24(9):1636-41. PubMed ID: 25304678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
    Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
    Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.